Database→Dihexa

Tier 4NeuroprotectionCognitivePREMIUM

Dihexa

Dihexa (N-Hexanoic-Tyr-Ile-(6)-Aminohexanoic Amide)

Not FDA-approved. No IND filed. Never investigated in humans. Available as a research chemical in the US. Fosgonimeton (pharmaceutical pro-drug) completed Phase 2/3 LIFT-AD which failed all endpoints (September 2024). All Athira clinical programs discontinued. WADA: Not on Prohibited List.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Dihexa is a synthetic angiotensin IV derivative proposed to amplify HGF/c-Met signaling. Its foundational mechanistic paper was formally retracted in April 2025 for research misconduct. Its pharmaceutical successor compound (fosgonimeton) failed all endpoints in a Phase 2/3 Alzheimer's trial (n=312, September 2024). Zero human clinical trials of dihexa itself exist. The c-Met proto-oncogene safety concern is completely uncharacterized.

🔒

Full Profile: Premium Members Only

The complete Dihexa profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use